FDA approves Vera Therapeutics kidney disease treatment
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA approves Vera Therapeutics kidney disease treatment" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Business Journals, Medical Professionals Reference, Fierce Pharma and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 131d ago.
Quick answers
Why is "FDA approves Vera Therapeutics kidney disease treatment" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (12)
- Vera Therapeutics wins FDA nod for closely watched kidney disease drug BioPharma Dive · 131d ago
- Vera Therapeutics Receives FDA Accelerated Approval for GlobeNewswire · 131d ago
- 🔎 Under the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDA WSJ · 131d ago
- Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy Yahoo Finance · 131d ago
- US FDA Approves Trutakna For Proteinuria In Primary Immunoglobulin A Nephropathy TradingView · 131d ago
- VERA Stock Set To Snap 3-Session Slide Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug Stocktwits · 131d ago
- What Trutakna's Approval Means for Specialty Launches Pharmaceutical Commerce · 131d ago
- 'I got back to living my normal life': How Vera Therapeutics' drug renewed a kidney patient ahead of FDA test The Business Journals · 131d ago
- Trutakna Approved to Reduce Proteinuria in Primary IgA Nephropathy Medical Professionals Reference · 131d ago
- FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka Fierce Pharma · 131d ago
- US FDA approves Vera's kidney disease drug Reuters · 131d ago
- FDA approves Vera Therapeutics kidney disease treatment STAT · 131d ago
Topics
Related trends
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.